2023-11-23 00:00:41
New study for patients with ulcerative colitis in the Medical Clinic II // East Hesse|News Home page Region Fulda district HEF-ROF Vogelsberg district Main-Kinzig Rhön district Blue light Politics Economy Church
State Garden Show
Sports Football Table Tennis Handball Service Jobs Speed Camera Imprint Data Protection
Over 200,000 sick in Germany
The Medical Clinic II offers treatment to those affected.
Photo: Klinikum Fulda gAG
23.11.2023 / FULDA –
Ulcerative colitis is one of the main forms of inflammatory bowel disease (IBD). Over 200,000 mostly young patients are suffering from it in Germany. The Medical Clinic II offers those affected treatment in the FRESCO study, which relies on a new treatment with few side effects.
Ulcerative colitis (UC) is a chronic disease in which pathological changes in the microbiota, i.e. the entirety of microorganisms in the intestine, are partly responsible for the disease flare-ups.
Current therapeutic measures with conventional medications, immunosuppressants, biologics and so-called “small molecules” are not always sufficient to control disease activity in the long term. There is therefore a need for new therapies with few side effects.
“It is a new concept for endoscopic chair transfer”
“As part of the study, patients with ulcerative colitis are treated with encapsulated stool or the supernatant of intestinal bacteria. This is a new concept to the endoscopic stool transfer that has already been used in several studies,” explains Prof. Dr. Carsten Schmidt, Director of the Medical Clinic II (Gastroenterology) at the Fulda Clinic. The aim of the study is to investigate whether fecal microbiota transfer (gut bacteria from healthy donors) in capsule form is effective and safe in treating people with mild to moderate ulcerative colitis.
“We are looking for affected patients”
“We are looking for affected patients who would like to take part in the FRESCO study,” says Professor Schmidt. This is a so-called randomized, double-blind, placebo-controlled study (RCT) that enables treatment with this new therapeutic option. Participation in this study lasts a total of around 24 weeks; a preliminary examination is carried out beforehand, followed by a visit after the end of treatment (52 weeks after the start of the study). During this time, study participants will visit the clinic approximately four to five times.
Requirements for participation
Requirements for participation in the study are: People with mild to moderately active ulcerative colitis between the ages of 18 and 75. Participation in the study is excluded for patients with Crohn’s disease, people who have already had colon surgery or who have been diagnosed with cancer in the last three years.
Patients interested in the FRESCO study are welcome to contact the study office by email: med2.sek@klini-kum-fulda.de) or at (0661) 84 – 5448. (pm) +++
Privacy Settings
X
1700697976
#study #patients #ulcerative #colitis #Medical #Clinic #OsthessenNews